Close

Next crop of COVID-19 vaccine developers take more traditional route

Go back to Next crop of COVID-19 vaccine developers take more traditional route

Moderna (MRNA) Misses Q3 EPS by 16c, Revenues Beat

October 29, 2020 7:48 AM EDT

Moderna (NASDAQ: MRNA) reported Q3 EPS of ($0.59), $0.16 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $157.91 million versus the consensus estimate of $77.51 million.

The Moderna team continued to execute on our plan in the third quarter. We now have... More